ArticleThe Biochemical journal2005
Direct comparison of the specificity of gene silencing using antisense oligonucleotides and RNAi.
Article in The Biochemical journal, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 53 citations in OpenAlex.
- Silencing with precision: In silico strategies for antisense oligonucleotide engineering.Molecular biology reports · 2026Review
- Exploring precision therapeutics: computational design of antisense oligonucleotides targeting AXL gene transcripts in multiple sclerosis treatment management.Frontiers in chemistry · 2025Article
- Discovery and functional characterization of LncRNAs associated with inflammation and macrophage activation.Methods (San Diego, Calif.) · 2024Review
- Continuous countercurrent chromatographic twin-column purification of oligonucleotides: The role of the displacement effect.Biotechnology and bioengineering · 2022Article
- High Concentration of an ISS-N1-Targeting Antisense Oligonucleotide Causes Massive Perturbation of the Transcriptome.International journal of molecular sciences · 2021Article
- Puromycin-resistant lentiviral control shRNA vector, pLKO.1 induces unexpected cellular differentiation of P19 embryonic stem cells.Biochemical and biophysical research communications · 2017Article
- Deletion of murine Arv1 results in a lean phenotype with increased energy expenditure.Nutrition & diabetes · 2015Article
- A Tandem Oligonucleotide Approach for SNP-Selective RNA Degradation Using Modified Antisense Oligonucleotides.PloS one · 2015Article
- The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis.Oncotarget · 2014Article
- Lentiviral vector-mediated RNA silencing in the central nervous system.Human gene therapy methods · 2014Review
- Molecular cloning and characterization of a novel anti-TLR9 intrabody.Cellular & molecular biology letters · 2013Article
- Investigation of Sub-100 nm Gold Nanoparticles for Laser-Induced Thermotherapy of Cancer.Nanomaterials (Basel, Switzerland) · 2013Article
- Illuminating the gateway of gene silencing: perspective of RNA interference technology in clinical therapeutics.Molecular biotechnology · 2012Review
- Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor.The Journal of biological chemistry · 2011Article
- Inhibition of pathologic immunoglobulin-free light chain production by small interfering RNA molecules.Experimental hematology · 2010Article
- A status report on RNAi therapeutics.Silence · 2010Article
- 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.Cancer research · 2009Article
- MicroRNA-like off-target transcript regulation by siRNAs is species specific.RNA (New York, N.Y.) · 2009Article
- Transient RNA silencing of tissue factor pathway inhibitor-2 modulates lung cancer cell invasion.Clinical & experimental metastasis · 2009Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
RNAi (RNA interference) and ASO (antisense oligonucleotide) technologies are the most commonly used approaches for silencing gene expression. However, the specificity of such powerful tools is an important factor to correctly interpret the biological consequences of gene silencing. In the present study, we examined the effects of acute loss of Ser/Thr kinase PDK1 (3-phosphoinositide-dependent kinase 1) expression using ASO and RNAi, and compared, for the first time, these two techniques using Affymetrix microarrays. We show that both ASO- and siRNA (small interfering RNA)-mediated knock-down of PDK1 expression strongly inhibited cell proliferation, although by different mechanisms, thereby questioning the specificity of these reagents. Using microarray analysis, we characterized the specificity of the ASO- and siRNA-mediated gene silencing of PDK1 by examining expression profiles 48 and 72 h following oligonucleotide transfection. At 48 h, a PDK1-dependent pattern of gene alterations was detectable, despite a large number of non-specific changes due to transfection of control nucleic acids. These non-specific alterations became more apparent at the 72 h time point, and obscured any PDK1-specific pattern. This study underscores the importance of defining appropriate control ASOs and siRNAs, using multiple oligonucleotides for each target and preferably short time points following transfection to avoid misinterpretation of the phenotype observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.